Semaglutide's impact on coronary flow reserve in diabetic and non-diabetic patients under investigation

Coronary artery disease (CAD) remains a leading cause of morbidity and mortality, often characterized by impaired coronary flow reserve (CFR), which reflects the heart's ability to increase blood supply during stress. Reduced CFR is an early indicator of microvascular dysfunction and predicts adverse cardiovascular events, even in the absence of obstructive epicardial disease. Current treatments for CAD often focus on risk factor modification and revascularization, but strategies directly improving microvascular function are limited. GLP-1 receptor agonists (GLP-1RAs) like semaglutide have demonstrated significant cardiovascular benefits beyond glycemic control and weight loss, including improvements in endothelial function and inflammation, suggesting a potential role in enhancing coronary microcirculation. This study aims to explore this specific vascular effect.

This observational study (NCT07190144) enrolled 122 patients, divided into diabetic and non-diabetic cohorts, who were already prescribed semaglutide by an endocrinology specialist primarily for weight management. Participants underwent baseline echocardiography to measure Coronary Flow Reserve (CFR). After 3 months of semaglutide treatment, CFR measurements were repeated using echocardiography. The primary objective was to assess changes in coronary artery flow in both groups following treatment. No specific dose of semaglutide was mentioned, as it was based on physician prescription.

The provided information is a clinical trial registration and does not contain any results or findings. The study status is "COMPLETED," but the abstract does not report any data, statistical analyses, or specific outcomes regarding changes in coronary flow reserve. Therefore, no specific numbers, p-values, or fold-changes can be reported at this time, as the findings have not yet been published or made available in this record.